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Abstract 
The relative lack of clinical success with conventional anticancer agents may be 
due in part to the traditional concept of cancer being a biological state rather 
than a dynamic process. Redefining cancer as a dynamic disease commencing 
with carcinogenesis introduces the possibility of chemoprevention. Retinoids 
offer the promise of a therapeutic option based on differentiation of 
premalignant as well as malignant cells. Research to date has concentrated on 
the use of exogenous retinoids in cancer. Although this research continues with 
new retinoid derivatives, an alternative approach to overcoming the drawbacks 
associated with exogenous retinoids has been to increase the levels of 
endogenous retinoic acid (RA) by inhibiting the cytochrome P450-  mediated 
catabolism of RA using a novel class of agents known as retinoic acid 
metabolism blocking agents (RAMBAs which increase the level of endogenous 
retinoic acid (RA) within the tumor cells by blocking their metabolism. This 
approach presents several theoretic advantages. 
In the present study a wide range of established P-450 inhibitors has been 
screened to examine their inhibitory activity on all-trans-Retinoic acid (ATRA) 
metabolism. Forty-one known P450 inhibitors were tested for their inhibitory 
activity against RA metabolism. Most of them are nitrogen-containing 
compounds. The results showed that among these compounds only six 
compounds (N-benzyl-2-phenylethanamine, itraconazole, chlorpromazine, 
5-chloro-1,3-benzoxazol-2-amine, proadifen and furazolidone) showed inhibition 
of RA metabolism which was > 50%. Ketoconazole and liarozole were also 
screened as standard potent inhibitors in the same system and gave 87.5% and 
89% inhibition, respectively. The results indicate that mostly azoles with 922  M. Ahmad:   
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substituents in positions other than the 1-position on the ring are very weak 
inhibitors of RA metabolism. The most effective inhibitors (ketoconazole, 
itraconazole, bifonazole and clotrimazole) are 1-substituted and possess 
relatively large aromatic groups in the molecule. 1-Substituted imidazoles bind 
to cytochrome P-450 with a very high affinity but substitution in the other 
position of the imidazole decreases the binding affinity. 
Keywords 
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Introduction 
Although significant advances have been made in the treatment of some malignancies, the 
prognosis of patients with metastasis tumors remains poor. Differentiating agents redirect 
cells toward their normal phenotype and therefore may reverse or suppress  evolving 
malignant lesions or prevent cancer invasion. In addition, they offer a potential alternative 
to the classic cytostatic drugs and indeed represent an attractive target for medicinal 
intervention. Retinoids (vitamin A and its natural metabolites and synthetic analogs) are 
currently the subject of intense biological interest stimulated by the discovery and 
characterization of retinoid receptor and the realization of these compounds as 
nonsteroidal small-molecule hormones [1, 2].  All-trans-retinoic acid (ATRA), the bio-
logically most active metabolite of vitamin A, plays a major role in cellular differentiation 
and proliferation of epithelial tissue. ATRA is being used in differentiation therapy of 
cancer, in cancer chemoprevention and for the treatment of acne [3–5]. Recently, ATRA 
has proven useful in cancer chemotherapy [6–8]. One of the most impressive effects of 
ATRA is on acute promyelocytic leukaemia. Treatment of acute promyelocytic leukaemia 
patients with high dose of ATRA resulted in complete  remission [9, 10]. Furthermore, 
several experiments in animals have demonstrated that ATRA inhibited the induction and 
caused the disappearance of prostate tumors [11]. In spite of these encouraging results, 
the effects of prolonged ATRA therapy on human cancers in the clinic has been scarce 
and disappointing [12]. It has been suggested that the therapeutic effects of ATRA are 
undermined by its rapid in vivo metabolism and catabolism by cytochrome P450 enzyme 
(CYPs) [13, 14]. 
One of the strategies for preventing in vivo catabolism of ATRA is to inhibit the P450 
enzyme(s) responsible for this process. Indeed, this seems to be an emerging approach 
that may yield effective agents for the chemoprevention and/or treatment of cancers [15]. 
This may create a novel  class of agents known as retinoic acid metabolism blocking 
agents (RAMBAs). Liarozole, a P-450 inhibitor (17, 20 steroid lyase) and the first RAMBA 
to undergo clinical investigation, preferentially increases intratumor levels of endogenous 
RA, resulting in antitumor activity [16]. This has opened up the possibility of developing 
more specific inhibitors of ATRA metabolism as a novel approach to cancer treatment. In 
the present study a wide range of established P450 inhibitors has been screened to 
examine their inhibitory activity on ATRA metabolism. 
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Materials and Methods 
Reagents 
N-benzyl-2-phenylethanamine  was purchased from Aldrich Chemical Company Ltd, 
2-methyl-5-phenyl-1,3-benzoxazole,  4-(4-bromophenyl)-1,2,3-thiadiazole,  5-(4-methyl-
phenyl)-1,2,4-thiadiazole,  5-(3-chlorophenyl)-1,3-oxazole  and  2-(thiophen-2-yl)-1,3,4-
oxadiazole were obtained from Maybridge Chemical Co Ltd. (Tintagel Cornwall). Liarozole 
was donated by Janssen Research Foundation (Bearse Belgium). All-trans-retinoic acid, 
NADPH, butylated hydroxyanisole and all the other P-450 inhibitors were purchased from 
Sigma Chemical Company. [11,12-
3H]-All-trans-retinoic acid (ATRA) was from DuPont 
(UK) Ltd. Formic acid, ammonium acetate and Hisafe III scintillation fluid (optiphase III) 
were obtained from Fisons Ltd. All solvents used for chromatography were of HPLC grade 
and were obtained from Rathburn Chemicals Ltd.UK. All other laboratory reagents were of 
analytical grade and obtained from British Drug House. 
Animals 
Healthy male wistar rats were fasted overnight and killed by stunning.  
Preparation of rat liver microsomes  
Rat liver microsomes were prepared by a previously described method [17] and stored at 
−80°C.  
RA Metabolism Assay 
The incubation system contained RA (3 μM, μl), NADPH (2 mM, 50 μl), inhibitor (100 μM, 
final concentration) in DMSO (10  μl),  phosphate  buffer  (50  mM,  pH  7.4)  up  to  a  final 
volume of 400 μl. The reaction was started by the addition of male rat hepatic microsomes 
(0.12 mg/ml, 10 μl) and the mixture incubated at 37°C. The reaction was terminated after 
15 min by addition of formic acid (1% 100 μl). 
3H.RA and its metabolites were extracted 
into ethyl acetate containing 0.05% (v/v) butylated hydroxyanisole (2x2 ml). The extract 
was dried out in vacuum at r. t. and the residue dissolved in the mobile phase used for the 
reverse phase. Controls (10 μl, DMSO) were also carried with each experiment. 
HPLC Separation of labeled material  
The assay followed a previously described one [17]: The column was a 10 μm  C18 μ 
Bondapak (3.9x 300mm, Millipore) and the mobile phase was acetonitrile: water: formic 
acid (75:25:0.05v/v) containing 10 mM ammonium acetate. Flow rate was 1.2 ml.Min
−1. 
Eluted 
3H compounds were detected on line by a model 970 detector (Reeve) using Hisafe 
III scintillation fluid. The retention time of 
3H-RA was 10 min and oxidative metabolites of 
3H-RA were detected, eluting samples over 3 to 7 min. Metabolism was determined from 
the % conversion of RA into its total metabolites based on AUC values. 
Determination of IC50 values for potent P-450 inhibitors of retinoic acid metabolism  
The IC50 values were determined for compounds exhibiting > 50% inhibition in the 
preliminary screening at 100 μM. 
The incubations were performed in triplicate using varying inhibitor concentrations in 
DMSO (10 μl) (as determined by preliminary experiments), RA  (3 μM, 10 μl), NADPH 924  M. Ahmad:   
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(2 mM, 50 ml),phosphate buffer (50 mM, pH 7.4, 320 μl) and male rat hepatic microsomes 
(0.12 mg/ml, 10 μl) at 37°C for 15 min. The reaction was terminated by addition of formic 
acid  (1%  100μl),  and  HPLC  analysis  was  performed  by  the  method  described  above. 
Three separate experiments (each with triplicate tubes) were carried out. 
Results 
Preliminary screening of P450 inhibitors on the in vitro inhibition of RA metabolism 
Forty-one known P450 inhibitors belonging to antifungal (mostly), analgesic, anticoagulant, 
anticonvulsants, antineoplastics, histamine, antihistamines and some miscellaneous drug 
classes were tested for their inhibitory activity against RA metabolism. Most of them are 
nitrogen-containing compounds. The results presented in table 1 showed that among 
these compounds only six compounds (N-benzyl-2-phenylethanamine, itraconazole, 
chlorpromazine, 5-chloro-1,3-benzoxazol-2-amine, proadifen and furazolidone) showed 
inhibition of RA metabolism which was >  50%. Ketoconazole and liarozole were also 
screened as standard potent inhibitors in the same system and gave 87.5% and 89% 
inhibition, respectively. 
Tab. 1.  In vitro inhibition of retinoic acid metabolism by P-450 inhibitors (100 μM). 
(Values are means of three determinations,(n=3), individual values differ from 
the mean by less than 3.1%. The symbol (-) denotes stimulation of RA 
metabolism). 
Antifungal Compounds 
(a) Imidazoles and related ring systems 
Compound  % Inhibition 
Liarozole   89.0 
Ketoconazole  87.5 
Itraconazole  68.7 
Bifonazole  47.5 
Clotrimazole  34.4 
Econazole  14.0 
Miconazole  13.5 
1-Benzylimidazole  7.6 
Sulconazole  8.7 
(a) Non imidazoles 
Compound  % Inhibition 
Griseofulvin  0.0 
Amphotericin  6.24 
Nystatin  5.44 
(c) Oxazoles and Thiazoles 
Compound  % Inhibition 
2-Methyl-5-phenyl-1,3-benzoxazole  18.0 
4-(4-Bromophenyl)-1,2,3-thiadiazole  11.6 
5-(4-Methylphenyl)-1,2,4-thiadiazole  4.8 
5-(3-Chlorophenyl)-1,3-oxazole  8.6 
2-(Thiophen-2-yl)-1,3,4-oxadiazole  0.0 
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Tab. 1.  (Cont.)  
Anthelmintic  
(Azoles) 
Compound  % Inhibition 
Tetramizole HCl  0.0 
Thiabendazole  −4.31 
Anticoagulants 
(Coumarin group) 
Compound  % Inhibition 
4-Hydroxycoumarin  38.50 
Coumarin  37.0 
7-Methoxycoumarin  11.7 
S-Warfarin  6.5 
R-Warfarin  3.0 
Analgesics 
Compound  % Inhibition 
Aspirin  5.0 
Paracetamol  3.5 
Diflunisal  2.0 
Indomethacin  0.0 
Ketoprofen  −3.5 
Antineoplastic 
(Aromatase inhibitors) 
Compound  % Inhibition 
Aminoglutethimide  30.8 
Nitroglutethimide  −1.4 
Anticonvulsants 
Compound  % Inhibition 
Nafimidone  12.0 
Phensuximide  3.5 
Histamine and Antihistamines 
Compound  % Inhibition 
Thiopermide maleate  3.4 
Cimetidine  1.0 
Histamine  0.0 
Anorectics 
(Benzphetamine and analogues) 
Compound  % Inhibition 
N-Benzyl-2-phenylethanamine  85.0 
Benzphetamine  46.0 
Miscellaneous Compounds 
Compound  % Inhibition 
Proadifen  86.0 
Chlorpromazine  85.0 
Furazolidone  54.0 
Phenobarbitone  0.0 926  M. Ahmad:   
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IC50 values for Potent Inhibitors of RA Metabolism 
The IC50 is the concentration of an inhibitor required to inhibit the enzyme by 50% at a 
given substrate concentration. IC50 were determined for compounds exhibiting > 50% 
inhibition in the preliminary screening at 100 μM. The IC50 for ketoconazole and liarozole 
were determined for comparative purposes. 
 
a 
 
b 
Fig. 1.  Determination of IC50 for ketoconazole (a) and itraconazole (b) 
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a 
 
b 
Fig. 2.  Determination of IC50 for N-benzyl-2-phenylethanamine (a) and 
Chlorpromazine (b) 
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b 
Fig. 3.  Determination of IC50 for 5-chloro-1,3-benzoxazol-2-amine (a) and Proadifen (b) 
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b 
Fig. 4.  Determination of IC50 for Liarozole (a) and Furazolidone (b) 
 
The IC50 was calculated from a plot of percentage inhibition versus log inhibitor 
concentration using Cricket Graph 1.3. These are shown in Fig 1–4. The IC50 values are 
summarized in table 2.  930  M. Ahmad:   
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Tab. 2.  IC50 values for some potent P-450 Inhibitors using male rat hepatic 
microsomes and retinoic acid as substrate (3μM).  
Compound  IC50 (μM) 
Proadifen    1.0 ± 0.14 
Liarozole    4.2 ± 0.1 
5-Chloro-1,3-benzoxazol-2-amine    6.5 ± 0.1 
Ketoconazole  13.5 ± 1.3 
Chlopromazine  16.9 ± 1.7 
N-Benzyl-2-phenylethanamine  17.1 ± 3.2 
Itraconazole  17.4 ± 1.0 
Furazolidone  88.5 ± 6.0 
Values are means ± S.D (n=3). 
 
Discussion 
Retinoic acid (RA) concentrations either too low or too high (normal serum RA levels   
0.5–7.0 ng/ml) adversely affect differentiation and maintenance of the tissues [18, 19]. 
Normal embryonic development also requires RA as a transcriptional regulator during 
specific times and at specific stages [20–22].  
A dose of 10 mg/ Kg body weight of RA has been shown to result in an approximately 
50-fold increase in the level of RA in mouse embryo limb buds and generally results in 
developmental abnormalities. While a dose of 1 mg / Kg, which is approximately 20 times 
higher than the daily dose of RA necessary to support adequate growth of vitamin A-
deficient animals produced no teratogenic effects in mice [23].  
Either abnormal concentrations of RA (either higher or lower than normal) or transiently 
inappropriate RA availability cause central nervous system, limb and craniofacial defects in 
mice [23, 24]. Therefore, maintaining the correct RA concentrations demands tight control 
over RA biosynthesis and metabolism. 
In contrast to retinal, which is stored in tissues and which displays stable plasma levels 
under regulation from the tissue stores, RA is rapidly metabolized in tissues and rapidly 
cleared from the plasma (t ½ < 1h) [25]. A cytochrome P450 (CYP) dependent oxidation in 
the 4 position of RA appears to be the rate limiting first step in the metabolism of RA to 
polar metabolites, the latter being biologically less active [25–27]. The significance of this 
catabolism of RA in relation to the biological and pharmacological effects of RA has 
received attention only recently. Warell and co-  workers noted that patients who had 
received exogenous RA chronically to induce the remission of acute promelocytic 
leukemia (APL) later presented with increased plasma clearance of RA due to induction of 
metabolism [28, 29]. The enhanced plasma clearance of RA may have contributed to the 
failure of RA therapy to maintain remissions in these APL patients. 
Liarozole fumarate is an imidazole cytchrome P450 inhibitor that has been shown to inhibit 
the metabolism of RA in in vitro tumour systems [30, 31]. Liarozole has shown significant 
antitumour effects in animal models and has clinical benefit in patients with advanced 
prostate cancers [32–34]. This anticancer activity owes part of its effectiveness to inhibition   Study on Cytochrome P-450 Dependent Retinoic Acid Metabolism and its Inhibitors as Potential …  931 
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of the oxidative metabolism of RA with a concomitant elevation of tumour RA levels. This 
has opened up the possibility of developing more specific inhibitors of RA metabolism as a 
novel approach to cancer treatment. In the present investigation a wide range of 
established P450 inhibitors has been screened to examine their inhibitory activity on RA 
metabolism.  
In the present studies different chemical ligands belonging to different chemical and 
pharmacological groups have been examined to study their possibility as RA metabolism 
inhibitor. The results indicate that mostly azoles with substituents in positions other than 
the 1-position on the ring are very weak inhibitors of RA metabolism. The most effective 
inhibitors (ketoconazole, itraconazole, bifonazole and clotrimazole) are 1-substituted and 
possess relatively large aromatic groups in the molecule. This reflects that 1-substituted 
imidazole bind to cytochrome P-450 with a very high affinity but substitution in the other 
position of the imidazole decreases the binding affinity. 
Njar et al. [35], have explained that introduction of azole group at C-4 of ATRA may yield 
specific and potent inhibitors of ATRA-4-hydroxylase. Indeed they have described the 
synthesis of a number of novel 4 azolyl ATRA derivatives, some of which are amongst the 
most potent inhibitors of this enzyme [35].  
Further study of these structure-activity relationships may provide useful lead compounds 
that could offer a novel approach to cancer treatment. 
Although several cytochrome P450 enzymes (CYPs) have been shown to be involved in 
the catalysis of ATRA 4-hydroxylation, their specificity for ATRA is generally low   
[28, 36–39]. Recently, a new family of cytochrome P450 enzymes, CYP26A1, has been 
cloned and characterized in zebra fish, human, and mouse tissues [40]. CYP26A1 is 
ATRA-inducible and appears to be the most dedicated ATRA 4-hydroxylase enzyme 
known [40].  
The compounds designed to inhibit CYP26A1 activity may be useful in elevating normal 
tissue ATRA levels or maintaining high therapeutic levels of ATRA. As such, it is an 
attractive pharmacological target for drug development when one aims to increase 
circulating or cellular RA concentrations. Further study of structure-activity relationships 
may provide useful lead compounds that could offer a novel approach to cancer treatment 
as does by liarozole for the treatment of prostate cancer [16 ]. 
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